BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9664292)

  • 21. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.
    Kruczynski A; Barret JM; Etiévant C; Colpaert F; Fahy J; Hill BT
    Biochem Pharmacol; 1998 Mar; 55(5):635-48. PubMed ID: 9515574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microtubule-binding natural products for cancer therapy.
    Yue QX; Liu X; Guo DA
    Planta Med; 2010 Aug; 76(11):1037-43. PubMed ID: 20577942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microtubulin binding sites as target for developing anticancer agents.
    Islam MN; Iskander MN
    Mini Rev Med Chem; 2004 Dec; 4(10):1077-104. PubMed ID: 15579115
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.
    Matthew S; Chen QY; Ratnayake R; Fermaintt CS; Lucena-Agell D; Bonato F; Prota AE; Lim ST; Wang X; Díaz JF; Risinger AL; Paul VJ; Oliva MÁ; Luesch H
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33619102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
    Shi Q; Chen K; Morris-Natschke SL; Lee KH
    Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microtubules as a target for anticancer drugs.
    Jordan MA; Wilson L
    Nat Rev Cancer; 2004 Apr; 4(4):253-65. PubMed ID: 15057285
    [No Abstract]   [Full Text] [Related]  

  • 28. Discovery of Inhibitors of Membrane Traffic from a Panel of Clinically Effective Anticancer Drugs.
    Kamata H; Sadahiro S; Yamori T
    Biol Pharm Bull; 2019 May; 42(5):814-818. PubMed ID: 30787205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.
    Dumontet C; Jaffrezou JP; Tsuchiya E; Duran GE; Chen KG; Derry WB; Wilson L; Jordan MA; Sikic BI
    Bull Cancer; 2004 May; 91(5):E81-112. PubMed ID: 15568225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.
    Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC
    Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.
    Pineda O; Farràs J; Maccari L; Manetti F; Botta M; Vilarrasa J
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4825-9. PubMed ID: 15341932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors.
    Combeau C; Provost J; Lancelin F; Tournoux Y; Prod'homme F; Herman F; Lavelle F; Leboul J; Vuilhorgne M
    Mol Pharmacol; 2000 Mar; 57(3):553-63. PubMed ID: 10692496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Progress of the Anticancer Agents Related to the Microtubules Target.
    Olatunde OZ; Yong J; Lu C
    Mini Rev Med Chem; 2020; 20(20):2165-2192. PubMed ID: 32727327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Energetics of vinca alkaloid interactions with tubulin isotypes: implications for drug efficacy and toxicity.
    Lobert S; Frankfurter A; Correia JJ
    Cell Motil Cytoskeleton; 1998; 39(2):107-21. PubMed ID: 9484953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators.
    Wilson L; Panda D; Jordan MA
    Cell Struct Funct; 1999 Oct; 24(5):329-35. PubMed ID: 15216890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro.
    Himes RH; Kersey RN; Heller-Bettinger I; Samson FE
    Cancer Res; 1976 Oct; 36(10):3798-802. PubMed ID: 954003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular effects of curcumin on Plasmodium falciparum include disruption of microtubules.
    Chakrabarti R; Rawat PS; Cooke BM; Coppel RL; Patankar S
    PLoS One; 2013; 8(3):e57302. PubMed ID: 23505424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.